Download PDF
Nephrologie aktuell 2023; 27(05): 221-228
DOI: 10.1055/a-2026-5196
Schwerpunkt
Nephrologie

Lipidsenkende Therapie bei chronischer Nierenerkrankung im Erwachsenenalter

Patientengerechte Anwendung aktueller Leitlinien
Reinhard Klingel
1   Apherese Forschungsinstitut, Köln
2   I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die chronische Nierenerkrankung (CKD: „chronic kidney disease“) wird entsprechend der Leitlinien des Netzwerks Kidney Disease: Improving Global Outcomes (KDIGO) unabhängig von der Ätiologie definiert als mindestens 3-monatige Einschränkung der Nierenfunktion mit meist irreversibler, struktureller Schädigung der Nieren, die bis zur terminalen Niereninsuffizienz fortschreiten kann. Kardiovaskuläre Erkrankungen stellen die Haupttodesursache bei Patienten mit CKD dar. Mit abnehmender glomerulärer Filtrationsrate (GFR) steigt die Bedeutung nicht atherosklerotischer Risikofaktoren. Diese komplexe Risikokonstellation führt zu den 2 allgemeinen Therapiezielen: die Verhinderung oder Verlangsamung der Progredienz der CKD unter Einschluss der möglichst effektiven Behandlung der Grunderkrankung und der kardiovaskulären Prävention. Hinsichtlich der Atherosklerose ist die lipidsenkende Therapie (LLT: „lipid-lowering therapy“) ein wesentliches Element mit den Empfehlungen des KDIGO-Netzwerks und den Leitlinien der European Society of Cardiology (ESC) als Grundlagen.



Publication History

Article published online:
08 June 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Kidney Disease: Improving Global Outcomes KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013; 03: 259-305
    Search in Google Scholar
  • 2 Matsushita K, van der Velde M, Astor BC. et al Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis of general population cohorts. Lancet 2010; 375: 2073-2081
    CrossrefPubMedSearch in Google Scholar
  • 3 Kaesler N, Schurgers LJ, Floege J. Vitamin K and cardiovascular complications in chronic kidney disease patients. Kidney Int 2021; 100: 1023-1036
    CrossrefPubMedSearch in Google Scholar
  • 4 Speer T, Schunk SJ, Fliser D. Chronische Nierenerkrankung – eine kardiovaskuläre Höchstrisikokonstellation. Internist 2020; 61: 340-348
    CrossrefPubMedSearch in Google Scholar
  • 5 Steiger S, Roissant J, Zarbock A. et al Secondary immunodeficiency related to kidney disease (SIDKD) – definition, unmet needs, and mechanisms. J Am Soc Nephrol 2022; 33: 259-278
    CrossrefPubMedSearch in Google Scholar
  • 6 Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet 2016; 388: 276-284
    CrossrefPubMedSearch in Google Scholar
  • 7 Aeschbacher-Germann M, Kaiser N, Speierer A. et al Lipid-lowering trials are not representative of patients managed in clinical practice: a systematic review and meta-analysis of exclusion criteria. J Am Heart Assoc 2023; 12: e026551
    CrossrefPubMedSearch in Google Scholar
  • 8 Esmeijer K, Dekkers OM, de Fijter JW. et al Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep 2019; 09: 16632
    CrossrefPubMedSearch in Google Scholar
  • 9 Su X, Zhang L, Lv J. et al Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis 2016; 67: 881-892
    CrossrefPubMedSearch in Google Scholar
  • 10 Walther CP, Richardson PA, Virani SS. et al Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant 2020; 35: 312-319
    PubMedSearch in Google Scholar
  • 11 Shin JI, Fine DM, Sang Y. et al Association of rosuvastatin use with risk of hematuria and proteinuria. J Am Soc Nephrol 2022; 33: 1767-1777
    CrossrefPubMedSearch in Google Scholar
  • 12 Nissen SE, Lincoff AM, Brennan D. et al Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New Engl J Med 2023; 388: 1353-1364
    CrossrefPubMedSearch in Google Scholar
  • 13 Charytan DM, Sabatine MS, Pedersen TR. et al Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol 2019; 73: 2961-2970
    CrossrefPubMedSearch in Google Scholar
  • 14 Igweonu-Nwakile EO, Ali S, Paul S. et al A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Cureus 2022; 14: e29140
    PubMedSearch in Google Scholar
  • 15 Toth PP, Dwyer JP, Cannon CP. et al Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 2018; 93: 1397-1408
    CrossrefPubMedSearch in Google Scholar
  • 16 Tunon J, Steg PG, Bhatt DL. et al Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEYOUTCOMES randomized clinical trial. Eur Heart J 2020; 41: 4114-4123
    CrossrefPubMedSearch in Google Scholar
  • 17 Lupo MG, Bressan A, Donato M. et al PCSK9 promotes arterial medial calcification. Atherosclerosis 2022; 346: 86-97
    CrossrefPubMedSearch in Google Scholar
  • 18 Ray KK, Raal FJ, Kallend DG. et al Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J 2023; 44: 129-138
    CrossrefPubMedSearch in Google Scholar
  • 19 Ference BA, Ginsberg HN, Graham I. et al Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J 2017; 38: 2459-2472
    CrossrefPubMedSearch in Google Scholar
  • 20 Grundy SM, Cleeman JI, Merz CNB. et al Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239
    CrossrefPubMedSearch in Google Scholar
  • 21 Mach F, Baigent C, Catapano AL. et al 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
    CrossrefPubMedSearch in Google Scholar
  • 22 Kronenberg F, Mora S, Stroes ESG. et al Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-3946
    CrossrefPubMedSearch in Google Scholar
  • 23 Bajaj A, Damrauer SM, Anderson AH. et al Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease. Arterioscler Thromb Vasc Biol 2017; 37: 1971-87
    CrossrefPubMedSearch in Google Scholar
  • 24 Hopewell JC, Haynes R, Baigent C. The role of lipoprotein(a) in chronic kidney disease. J Lipid Res 2018; 59: 577-585
    CrossrefPubMedSearch in Google Scholar
  • 25 Collins R, Reith C, Emberson J. et al Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561
    CrossrefPubMedSearch in Google Scholar
  • 26 Cholesterol Treatment Trialists’ (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681
    CrossrefPubMedSearch in Google Scholar
  • 27 Nicholls SJ, Puri R, Anderson T. et al Effect of evolocumab on progression of coronary disease in statin-treated patients – the GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-2384
    CrossrefPubMedSearch in Google Scholar
  • 28 Baigent C, Landray MJ, Reith C. et al The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
    CrossrefPubMedSearch in Google Scholar
  • 29 Cholesterol Treatment Trialists’ (CTT) Collaboration Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 04: 829-839
    CrossrefPubMedSearch in Google Scholar
  • 30 Lamprea-Montealegre JA, Staplin N, Herrington WG. et al Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD. Clin J Am Soc Nephrol 2020; 15: 47-60
    CrossrefPubMedSearch in Google Scholar
  • 31 Szummer K, Lundman P, Jacobson SH. et al Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 2011; 79: 997-1004
    CrossrefPubMedSearch in Google Scholar
  • 32 Matthew RO, Maron DJ, Anthopolos R. et al Guideline-directed medical therapy attainment and outcomes in dialysis-requiring versus nondialysis chronic kidney disease in the ISCHEMIA-CKD trial. Circ Cardiovasc Qual Outcomes 2022; 15: e008995
    CrossrefPubMedSearch in Google Scholar
  • 33 Rossing P, Caramori ML, Chan JCN. et al Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102: 990-999
    CrossrefPubMedSearch in Google Scholar
  • 34 Wanner C. KDIGO-Leitlinien zum Lipidmanagement bei chronischen Nierenerkrankungen. Nephrologe 2014; 09: 46-47
    CrossrefSearch in Google Scholar
  • 35 Schneider MP, Hübner S, Titze SI. et al Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney Int 2015; 88: 1411-1418
    CrossrefPubMedSearch in Google Scholar
  • 36 Visseren FLJ, Mach F, Smulders YM. et al 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2022; 29: 5-115
    CrossrefPubMedSearch in Google Scholar
  • 37 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinie/AM-RL) zuletzt geändert am 19. Januar 2023, veröffentlicht im Bundesanzeiger (BAnz AT 06.03.2023 B3)
  • 38 Chen J, Budoff MJ, Reilly MP. et al Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol 2017; 02: 635-643
    CrossrefPubMedSearch in Google Scholar
  • 39 August P. Chronic kidney disease – another step forward. New Engl J Med 2023; 388: 179-180
    CrossrefPubMedSearch in Google Scholar
  • 40 Vart P, Vaduganathan M, Jongs N. et al Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes. Clin J Am Soc Nephrol 2022; 17: 1754-1762
    CrossrefPubMedSearch in Google Scholar
  • 41 Kimura H, Tanaka K, Saito H. et al Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol 2021; 16: 1797-1804
    CrossrefPubMedSearch in Google Scholar